{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1259332259", "close" : "1259344859", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
globenewswire

Athersys to Host Third Quarter 2009 Financial Results Call

  • Press Release
  • Source: Athersys, Inc.
  • On 11:00 am EDT, Tuesday October 20, 2009

CLEVELAND, Oct. 20, 2009 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX - News) today announced it will release its third quarter 2009 financial results at approximately 4:00 PM (Eastern Time) on Thursday, November 5, 2009, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call.

Related Quotes

SymbolPriceChange
ATHX0.99-0.01
Chart for Athersys, Inc.
{"s" : "athx","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Investors and other interested parties are invited to listen to the conference call by dialing 800-273-1254 in the U.S. and Canada, 973-638-3440 from abroad, or via a live Internet broadcast at the company's website at www.athersys.com, under the Investor Relations section.

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM (Eastern Time) on November 19, 2009, at the aforementioned URL, or by dialing 800-642-1687 in the U.S. and Canada, or 706-645-9291 from abroad, and entering access code 36174982.

About Athersys, Inc.

Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem(R), a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). More information is available at www.athersys.com.

The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548

Contact:

Athersys 
William (B.J.) Lehmann, J.D., President and COO
(216) 431-9900
bjlehmann@athersys.com
In-Site Communications, Inc.
Investor Relations:
Lisa M. Wilson
(917) 543-9932
lwilson@insitecony.com
Lambert, Edwards & Associates
Media:
Dave Buckalew
(616) 233-0500
dbuckalew@lambert-edwards.com

Sponsored Links

Copyright © 2009 GlobeNewswire. All rights reserved. Redistribution of this content is expressly prohibited without prior written consent. GlobeNewswire makes no claims concerning the accuracy or validity of the information, and shall not be held liable for any errors, delays, omissions or use thereof.